Antiemetics and Antinauseants Market Report 2026

The antiemetics and antinauseants market size has grown steadily in recent years. It will grow from $8.48 billion in 2025 to $8.72 billion in 2026 at a compound annual growth rate (CAGR) of 2.8%. The growth in the historic period can be attributed to increasing cancer incidence, growth in surgical procedures, rising awareness of chemotherapy side effects, expansion of hospital and clinic infrastructure, advances in antiemetic drug formulations.

The antiemetics and antinauseants market size is expected to see steady growth in the next few years. It will grow to $10.01 billion in 2030 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to increasing prevalence of motion sickness, growth in global geriatric population, rising adoption of personalized medicine, innovations in novel antiemetic drug delivery systems, expansion of outpatient chemotherapy and palliative care services. Major trends in the forecast period include personalized anti-nausea therapy development, novel drug delivery systems, combination therapy approaches, rising demand for chemotherapy supportive care, growth in motion sickness and travel-related treatments.

The rising prevalence of tuberculosis (TB) is expected to drive the growth of the antiemetics and antinauseants market. TB is an infectious bacterial disease that primarily affects the lungs. Antiemetics and antinauseants are used to manage nausea and vomiting caused by anti-tuberculosis medications. For instance, in March 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported 10,347 tuberculosis cases in the United States in 2024, representing a rate of 3 cases per 100,000 population - an increase of approximately 8% compared with 2023. This growing prevalence of TB highlights the increasing need for supportive treatments, including antiemetics and antinauseants.

Additionally, the increasing number of surgeries is driving the antiemetics and antinauseants market. Surgical procedures often lead to postoperative nausea and vomiting due to anesthesia or operative interventions. For instance, in April 2025, the Australian Institute of Health and Welfare reported 778,500 public hospital admissions from elective surgery waitlists in 2023-24, a 5.8% increase compared to 2022-23. The growing volume of surgical procedures is therefore boosting demand for antiemetic and antinauseant therapies.

Major companies in this market are focusing on product innovations, such as ready-to-use injectables, to simplify treatment and improve patient compliance. For example, in July 2024, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched FOCINVEZ, the first ready-to-use injectable fosaprepitant formulation for preventing acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy. This 150 mg/50 mL vial requires no reconstitution, enabling direct administration and use in adults and pediatric patients aged six months and older.

Major companies operating in the antiemetics and antinauseants market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Pharma Co. Ltd., Daiichi Sankyo Company, Braun GmbH, Eisai Co. Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, IPCA Laboratories Ltd., Eagle Pharmaceuticals Inc., Cadila Pharmaceuticals Ltd., Bristol Laboratories Ltd., Tesaro Inc., SRS Pharmaceuticals Pvt. Ltd., Acacia Pharma Ltd., Algen Healthcare Ltd., Mirabilia Sciences Pvt. Ltd., Helsinn Healthcare SA.

North America was the largest region in the drugs for antiemetics and antinauseants market in 2025. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the antiemetics and antinauseants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the antiemetics and antinauseants market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized excipients, leading to higher production costs for manufacturers. The chemotherapy supportive care segment and motion sickness treatment drugs are particularly impacted, especially in regions like North America and Europe that rely on imported raw materials. While costs have risen, some domestic manufacturers benefit from tariffs as it encourages local sourcing and production, potentially boosting local pharmaceutical manufacturing and innovation in cost-efficient formulations.

The antiemetics and antinauseants market research report is one of a series of new reports that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with a antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antiemetics and antinauseants are drugs used to prevent or manage vomiting caused by emetogenic chemotherapy, as well as postoperative nausea and vomiting. They help control nausea and vomiting triggered by medications, motion sickness, infections, stomach flu, or chemotherapy by blocking signals to the brain’s vomiting center.

The main drug types in antiemetics and antinauseants include dopamine antagonists, NK1 receptor antagonists, antihistamines (H1 receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids, 5-HT3 receptor antagonists, and others. Dopamine antagonists, also known as anti-dopaminergic or dopamine receptor antagonists, block dopamine receptors and are used to treat nausea and vomiting from chemotherapy, motion sickness, gastroenteritis, general anesthesia, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and other causes. These drugs are administered in hospitals, medical centers, clinics, and research institutes.

The antiemetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.